US20140271851A1 - Antiemetic extended release solid dosage forms - Google Patents

Antiemetic extended release solid dosage forms Download PDF

Info

Publication number
US20140271851A1
US20140271851A1 US14/212,954 US201414212954A US2014271851A1 US 20140271851 A1 US20140271851 A1 US 20140271851A1 US 201414212954 A US201414212954 A US 201414212954A US 2014271851 A1 US2014271851 A1 US 2014271851A1
Authority
US
United States
Prior art keywords
ondansetron
pharmaceutical formulation
core
release
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/212,954
Other languages
English (en)
Inventor
Reza Fathi
Gilead Raday
Patrick Gosselin
Guy Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140271851(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Priority to US14/212,954 priority Critical patent/US20140271851A1/en
Publication of US20140271851A1 publication Critical patent/US20140271851A1/en
Assigned to REDHILL BIOPHARMA LTD. reassignment REDHILL BIOPHARMA LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FATHI, REZA, RADAY, Gilead, GOLDBERG, Guy, GOSSELIN, PATRICK
Priority to US15/678,386 priority patent/US20180028452A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US14/212,954 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms Abandoned US20140271851A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/212,954 US20140271851A1 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms
US15/678,386 US20180028452A1 (en) 2013-03-14 2017-08-16 Antiemetic extended release solid dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782395P 2013-03-14 2013-03-14
US14/212,954 US20140271851A1 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/678,386 Continuation US20180028452A1 (en) 2013-03-14 2017-08-16 Antiemetic extended release solid dosage forms

Publications (1)

Publication Number Publication Date
US20140271851A1 true US20140271851A1 (en) 2014-09-18

Family

ID=51528070

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/212,694 Active 2034-05-21 US9636305B2 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms
US14/212,954 Abandoned US20140271851A1 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms
US15/466,214 Abandoned US20170189340A1 (en) 2013-03-14 2017-03-22 Antiemetic extended release solid dosage forms
US15/678,386 Abandoned US20180028452A1 (en) 2013-03-14 2017-08-16 Antiemetic extended release solid dosage forms
US16/918,538 Abandoned US20200330392A1 (en) 2013-03-14 2020-07-01 Bimodal release ondansetron tablets and methods of treating nausea and vomiting

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/212,694 Active 2034-05-21 US9636305B2 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/466,214 Abandoned US20170189340A1 (en) 2013-03-14 2017-03-22 Antiemetic extended release solid dosage forms
US15/678,386 Abandoned US20180028452A1 (en) 2013-03-14 2017-08-16 Antiemetic extended release solid dosage forms
US16/918,538 Abandoned US20200330392A1 (en) 2013-03-14 2020-07-01 Bimodal release ondansetron tablets and methods of treating nausea and vomiting

Country Status (19)

Country Link
US (5) US9636305B2 (ja)
EP (1) EP2983664B1 (ja)
JP (1) JP6282676B2 (ja)
KR (1) KR102270521B1 (ja)
CN (2) CN112274489A (ja)
AU (1) AU2014264342B2 (ja)
BR (1) BR112015022398B1 (ja)
CA (1) CA2905553C (ja)
CL (1) CL2015002666A1 (ja)
ES (1) ES2946985T3 (ja)
HK (1) HK1223012A1 (ja)
IL (1) IL241580B (ja)
MX (1) MX2015012970A (ja)
NZ (1) NZ712159A (ja)
PH (1) PH12015502093A1 (ja)
RU (1) RU2679448C2 (ja)
SG (1) SG11201507450TA (ja)
WO (2) WO2014181195A2 (ja)
ZA (1) ZA201506961B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522119B2 (en) 2014-07-15 2016-12-20 Isa Odidi Compositions and methods for reducing overdose
US9636305B2 (en) 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
US9675588B2 (en) 2014-03-11 2017-06-13 Redhill Biopharma Ltd. Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
US11969416B1 (en) * 2022-11-03 2024-04-30 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102300335B1 (ko) * 2018-10-19 2021-09-10 주식회사 삼양홀딩스 아프레피탄트의 경구용 조성물

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US20020071863A1 (en) * 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
WO2003013482A1 (en) * 2001-08-03 2003-02-20 Strakan Group Limited Transdermal delivery of 5-ht3 antagonists
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US20050287211A1 (en) * 2004-04-30 2005-12-29 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US20100028420A1 (en) * 2006-12-22 2010-02-04 3M Innovative Properties Company Controlled release composition and process
US20100196291A1 (en) * 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
US20120010213A1 (en) * 2009-03-04 2012-01-12 Fdc Limited Oral controlled release dosage forms for water soluble drugs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
ATE359079T1 (de) 2003-01-13 2007-05-15 Dynogen Pharmaceuticals Inc Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
WO2005046700A1 (ja) 2003-11-14 2005-05-26 Senju Pharmaceutical Co., Ltd. アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
ATE553754T1 (de) * 2006-08-18 2012-05-15 Evonik Roehm Gmbh Pharmazeutische zusammensetzung mit kontrollierter wirkstoffabgabe für wirkstoffe mit guter löslichkeit in wasser
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004439A (es) 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
BR112012015282A2 (pt) * 2009-12-22 2016-03-15 Abbott Healthcare Private Ltd composição farmacêutica de liberação controlada
JP2013515782A (ja) 2009-12-28 2013-05-09 モノソル アールエックス リミテッド ライアビリティ カンパニー オンダンセトロンを含む経口投与可能なフィルム製剤
US8916194B2 (en) 2010-08-30 2014-12-23 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) * 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
BR112015022398B1 (pt) 2013-03-14 2022-01-11 Redhill Biopharma Ltd Comprimido de ondansetrona e preparação farmacêutica embalada

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US20020071863A1 (en) * 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
WO2003013482A1 (en) * 2001-08-03 2003-02-20 Strakan Group Limited Transdermal delivery of 5-ht3 antagonists
US20050287211A1 (en) * 2004-04-30 2005-12-29 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US20100028420A1 (en) * 2006-12-22 2010-02-04 3M Innovative Properties Company Controlled release composition and process
US20100196291A1 (en) * 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
US20120010213A1 (en) * 2009-03-04 2012-01-12 Fdc Limited Oral controlled release dosage forms for water soluble drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Opadry YS-1-7006 Technical Data Sheet (2011) *
Pygall et al. International Journal of Pharmaceutics 2009 379:110-120 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636305B2 (en) 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
US9675588B2 (en) 2014-03-11 2017-06-13 Redhill Biopharma Ltd. Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
US9522119B2 (en) 2014-07-15 2016-12-20 Isa Odidi Compositions and methods for reducing overdose
US9700515B2 (en) 2014-07-15 2017-07-11 Isa Odidi Compositions and methods for reducing overdose
US9700516B2 (en) 2014-07-15 2017-07-11 Isa Odidi Compositions and methods for reducing overdose
US9801939B2 (en) 2014-07-15 2017-10-31 Isa Odidi Compositions and methods for reducing overdose
US10293046B2 (en) 2014-07-15 2019-05-21 Intellipharmaceutics Corp. Compositions and methods for reducing overdose
US10653776B2 (en) 2014-07-15 2020-05-19 Intellipharmaceutics Corp. Compositions and methods for reducing overdose
US11969416B1 (en) * 2022-11-03 2024-04-30 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Also Published As

Publication number Publication date
BR112015022398A8 (pt) 2019-11-26
EP2983664A4 (en) 2017-01-04
CL2015002666A1 (es) 2017-02-17
US20200330392A1 (en) 2020-10-22
WO2014184662A2 (en) 2014-11-20
PH12015502093B1 (en) 2016-01-18
CN112274489A (zh) 2021-01-29
CA2905553A1 (en) 2014-11-13
RU2015143993A3 (ja) 2018-03-21
ES2946985T3 (es) 2023-07-31
KR20150127253A (ko) 2015-11-16
HK1223012A1 (zh) 2017-07-21
PH12015502093A1 (en) 2016-01-18
RU2679448C2 (ru) 2019-02-11
AU2014264342B2 (en) 2017-05-18
WO2014184662A3 (en) 2015-04-02
KR102270521B1 (ko) 2021-06-30
JP6282676B2 (ja) 2018-02-21
IL241580B (en) 2020-08-31
CN105530935A (zh) 2016-04-27
US20170189340A1 (en) 2017-07-06
US20180028452A1 (en) 2018-02-01
ZA201506961B (en) 2017-03-29
MX2015012970A (es) 2016-04-11
BR112015022398A2 (pt) 2017-07-18
SG11201507450TA (en) 2015-10-29
US20140271887A1 (en) 2014-09-18
BR112015022398B1 (pt) 2022-01-11
US9636305B2 (en) 2017-05-02
RU2015143993A (ru) 2017-04-20
NZ712159A (en) 2019-12-20
CA2905553C (en) 2021-04-06
WO2014181195A2 (en) 2014-11-13
EP2983664A2 (en) 2016-02-17
WO2014181195A3 (en) 2015-12-17
JP2016512493A (ja) 2016-04-28
EP2983664B1 (en) 2023-04-19
AU2014264342A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
US20180028452A1 (en) Antiemetic extended release solid dosage forms
US20120231080A1 (en) Controlled release dosage forms
US20060193912A1 (en) Controlled release O-desmethylvenlafaxine formulations
JP2006306893A (ja) 高度に可溶性の薬物のための徐放性マトリックス系
JP6059143B2 (ja) 溶出改善されたメサラジン錠
CN107530337B (zh) 治疗方法
US20200253933A1 (en) Methods for treating diarrhea predominant irritable bowel syndrome
JP2018154586A (ja) 錠剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: REDHILL BIOPHARMA LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FATHI, REZA;RADAY, GILEAD;GOSSELIN, PATRICK;AND OTHERS;SIGNING DATES FROM 20140410 TO 20140911;REEL/FRAME:034106/0526

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION